US Patent

US10420734 — Method of treating cancer using selective estrogen receptor modulators

Method of Use · Assigned to Duke University · Expires 2036-10-03 · 10y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating estrogen receptor positive brain cancer and cancer resistant to estrogen receptor modulators using selective estrogen receptor degraders.

USPTO Abstract

Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3524`	—	elacestrant-hydrochloride
`U-3524`	—	elacestrant-hydrochloride

Patent Metadata

Patent number: US10420734
Jurisdiction: US
Classification: Method of Use
Expires: 2036-10-03
Drug substance claim: No
Drug product claim: No
Assignee: Duke University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.